Brokers Offer Predictions for Merck & Co., Inc.’s Q4 2025 Earnings (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) – Equities researchers at Leerink Partnrs boosted their Q4 2025 earnings per share estimates for Merck & Co., Inc. in a research report issued on Saturday, April 20th. Leerink Partnrs analyst D. Graybosch now anticipates that the company will earn $2.39 per share for the quarter, up from their previous forecast of $2.37. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $8.59 per share.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The firm had revenue of $14.63 billion during the quarter, compared to analyst estimates of $14.49 billion. During the same period in the prior year, the company posted $1.62 earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year.

A number of other analysts have also weighed in on the company. Societe Generale lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a research note on Monday, March 11th. StockNews.com upgraded Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. UBS Group raised their target price on Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. TheStreet lowered Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. Finally, TD Cowen upgraded Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price target for the company from $125.00 to $135.00 in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus price target of $131.25.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $126.94 on Tuesday. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $133.10. The firm has a market cap of $321.54 billion, a PE ratio of 906.71, a price-to-earnings-growth ratio of 1.63 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.00 and a current ratio of 1.25. The business has a fifty day moving average of $126.24 and a 200-day moving average of $115.51.

Institutional Investors Weigh In On Merck & Co., Inc.

Hedge funds have recently modified their holdings of the business. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $27,000. Bare Financial Services Inc acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Burkett Financial Services LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $28,000. Rakuten Securities Inc. acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $30,000. Finally, RIA Advisory Group LLC acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $30,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insiders Place Their Bets

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Steven Mizell sold 50,694 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.